Hypnotic Dependence and Rebound Insomnia After Abrupt Discontinuation
A 61-year-old woman with a 12-year history of nightly zolpidem 10 mg presents requesting a refill. She has been escalating to 15 mg on stressful nights and reports early-morning awakenings and daytime fatigue. She has no history of sleep apnea symptoms, restless legs, or depression, but she has mild anxiety. She tried stopping abruptly 3 months ago and had two nights of severe rebound insomnia, after which she resumed the medication. She wants to stop but is afraid of "not sleeping at all." Her current sleep schedule is 11 pm to 5 am, with a 30-minute wind-down. She drinks two cups of coffee before noon and one glass of wine most evenings.
1. What is the differential for her persistent insomnia and dependence, and what assessment would you perform before designing a taper?
Read the worked answer
Consider hypnotic dependence with rebound insomnia, inadequate sleep opportunity (6 hours in bed is short for her age and may be perpetuating fatigue), conditioned arousal/psychophysiological insomnia, alcohol-related sleep fragmentation, anxiety, and less likely an unrecognized primary sleep disorder. Assessment should include a detailed sleep history and 1-2 weeks of sleep diary (or actigraphy), a review of caffeine/alcohol timing, screening for depression/anxiety and for sleep apnea and restless legs, and clarification of her goals. The short sleep window and evening alcohol are both modifiable and may be contributing to the early-morning awakenings and fatigue.
2. Outline a structured discontinuation plan, including the role of CBT-I and how you would manage rebound.
Read the worked answer
Use a gradual, supervised taper rather than abrupt cessation, paired with CBT-I as the core treatment. Steps: (1) set a realistic sleep window and consistent rise time, and address alcohol and caffeine; (2) begin CBT-I components-stimulus control, sleep restriction to consolidate sleep, cognitive restructuring about catastrophic thoughts about sleep; (3) reduce the zolpidem dose in small steps (e.g., 10 mg to 5 mg, then to 5 mg on alternate nights, then stop) over weeks, with the pace adjusted to tolerance; (4) anticipate 1-2 weeks of rebound insomnia and warn her in advance so she does not interpret it as failure; (5) avoid substituting another sedative-hypnotic; (6) schedule follow-up during the taper. Reassure her that CBT-I has durable benefits and that rebound is time-limited.
3. She asks whether she can just switch to another sleeping pill instead. How do you respond, and what are the safety considerations?
Read the worked answer
Explain that switching hypnotics does not address the underlying conditioned insomnia and carries its own risks, particularly in an older adult: falls, cognitive effects, and dependence. Non-benzodiazepine Z-drugs and benzodiazepines both carry dependence and rebound risk, and sedating antidepressants or antihistamines are not first-line for chronic insomnia and have their own adverse effects. The evidence-based, durable approach is CBT-I, with medication used only short-term and cautiously if needed. Document the discussion and her preferences.